The Peterson Health Technology Institute (PHTI) announced today that its initial assessments will focus on remote patient monitoring (RPM) for diabetes management and virtual musculoskeletal care. These assessment reports will inform payers, providers, and patients on the clinical and economic impact of the technologies and will be released and freely available online early next year.

As 80% of digital health products lack clinical evidence and many are not subject to U.S. Food and Drug Administration review, PHTI, which launched in July, will also evaluate several other timely, high-impact clinical areas in 2024.

PHTI will conduct its evaluations using a custom assessment framework, made public last month, which assesses the technology’s clinical benefits and economic impact, as well as effects on health equity, privacy, and security. The evaluations aim to identify the most promising aspects of digital health innovation, accelerating the adoption of high-value technology in healthcare.

“PHTI is targeting digital health tools that address complex health problems and have high potential to improve outcomes and affordability for both patients and payers,” said Caroline Pearson, Executive Director of the Peterson Center on Healthcare. “We will gather insights from stakeholders across the healthcare industry to provide input about which key areas of health technology would benefit from our independent evaluations.”

Technology Categories for Initial Assessments
PHTI’s first assessments will focus on RPM for diabetes management and virtual care for musculoskeletal conditions. Each represents a robust set of technology-enabled interventions that claim to deliver clinical outcomes, better treatment adherence, and an improved user experience. PHTI’s evaluations will review and analyze the evidence in each of these categories and provide information to guide healthcare purchasers’ decision-making about these tools.

Source: Company Press Release